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(34%) and VA respondents (VA-MS 34%, MH/SA 27%, VA-ADR 40%). HHA and SNF
respondents reported a similar average maximum number of daily injections per
patient (2.7 and 2.9, respectively). Whereas, almost half of the HHA respondents
reported restrictions on the number of daily nurse-administered injections that
can be delivered (14% also reported that their agencies restricted the types of in-
sulin that nurses can administer), only 10% of the VA-ADR and none of the SNF
respondents reported any restrictions on the number of injections (about 18% of
VA-MS and VA-ADR respondents reported restrictions on the type of insulin).
CONCLUSIONS: Insulin treatment patterns and restrictions on T2D patients vary
across settings, sometime substantially. There is evidence that care, as measured
by nurse administered insulin injections, may be more restricted in home health-
care than in institutional settings such as SNFs and VA facilities.
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OBJECTIVES: Out-of-pocket (OOP) cost as a component of insurance benefit design
has been found to be a barrier to medication adherence or use of preventive care.
This study aimed to assess the association of OOP share of total healthcare expen-
diture (THE) with diabetes monitoring in the United States.METHODS: This cross-
sectional study analyzed the household component data from the 2009 Medical
Expenditure Panel Survey (MEPS). According to the American Diabetes Association
guidelines, proper monitoring was defined as at least two A1c tests along with one
eye or foot examination annually. The OOP share wasmeasured by the percentage
of annual self-paid healthcare expenses out of THE. Insurance coverage was cate-
gorized into any private, public only and uninsured. Logistic regression models
were employed to control for social-demographics, health status, and treatments
among subpopulations with different insurance coverage. Estimates were
weighted to the total population (WTP). RESULTS: Among 2,445 (WTP: 19,780,759)
individuals with diabetes, 66.07% received proper monitoring. Well-monitored in-
dividuals had a lower OOP share (20.10% vs. 26.69%) than those that did not receive
services. Individuals with private insurance, public insurance, and no insurance
reported different OOP share: 21.79%, 15.65%, and 53.30%, respectively. The logistic
regressions indicated that individuals bearing high OOP share were less likely to
receive propermonitoring among individuals with private insurance and no insur-
ance [odds ratio (OR)0.99, 95% confidence interval (95%CI) 0.981-0.999, OR0.98,
95%CI0.975-0.987, respectively]. OOP share was not a significant factor in public
insurance beneficiaries. Other risk factors included older age, race/ethnic minori-
ties, use of oral antihyperglycemic medications and insulin, and worse health
status. CONCLUSIONS: Nearly one-third Americans with diabetes did not receive
proper diabetes monitoring in 2009. The OPP share was inversely associated with
receiving propermonitoring, suggesting the OOP share should be considered in the
benefit design for preventive care, particularly among the privately insured.
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OBJECTIVES: Health care resource utilization and costs may be indicators of dis-
ease severity and overall health status. In observational studies, these factors could
influence patients’ probability of receiving or benefiting from a particular treat-
ment. We compared pre-index utilization and costs in diabetes patients initiating
saxagliptin versus other non-insulin anti-diabetic regimens.METHODS: Individu-
als age 18 years and with evidence of T2DM (ICD-9-CM 250.x0 or 250.x2) were
identified from a US health plan database. Patients with 1 pharmacy claim for
saxagliptin (SAXA) betweenAugust 1, 2009 andDecember 31, 2010were assigned to
the SAXA cohort, and patients with1 pharmacy claim (August 1, 2009-December
31, 2010) for other oral anti-diabeticmedications or GLP-1 analogs were assigned to
the Other cohort. Patients were required to be naive to SAXA or the Other regimen
for 12 months prior to the index pharmacy claim. Utilization and costs were mea-
sured during a 12 month (pre-index) period before treatment initiation. RESULTS:
Pre-index, the SAXA cohort (N4763) had higher rates of all-cause ambulatory
visits (14.7 vs. 13.9; p0.001) and diabetes-related ambulatory visits (5.1 vs. 3.5;
p0.001) versus the Other cohort (N75,943). SAXA patients had higher pre-index
all-cause pharmacy costs ($2808 vs. $1660; p0.001) and diabetes-related total
costs than Other patients ($3683 vs. $2854; p0.001), driven by higher diabetes-
related ambulatory and pharmacy costs (both p0.001). SAXA patients, however,
had lower counts of pre-index all-cause and diabetes-related inpatient visits, all-
cause ED visits, and lower all-cause inpatient and ED costs than the Other cohort.
CONCLUSIONS: In a managed health care setting, pre-index resource utilization
and costs of patients initiating SAXA were higher for ambulatory services and
pharmacy, but ED visits and inpatient stays were lower, compared with patients
initiating other anti-diabetic regimens. These findings suggest SAXA prescribing
patterns could be influenced by differences in patients’ pre-index clinical charac-
teristics and risk profiles, such as difficulty achieving glycemic control in the pre-
index period.
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OBJECTIVES:To estimate the hospitalizations and its costs that can be attributed to
diabetesmellitus (DM) among hospitalizations occurred in Brazilian Public Health-
care System (SUS) between 2008-2010. METHODS: Number of hospitalization and
associated costs for study period was obtained through a review of government
administrative claims database (DATASUS). Hospitalizations with a first-listed di-
agnosis of diabetes were added to hospitalizations estimated to be due to diabetes
by attributable risk methodology (ARM). ARM is based on the formula: RAPi  [P x
(RRi - 1)] / [P x (RRi - 1)1], where RAPi is the fraction of population attributable risk
for medical condition i due to diabetes, P represents prevalence rate of diabetes,
and RRi is the relative risk of medical condition i for people with diabetes com-
pared to those without it (ADA, 2003). Diabetes prevalence was obtained from
VIGITEL-2006, a nationwide random telephonic sample (54,369 individuals). Self-
reported and expanded estimates according to diagnosis rate were used. Relative
risks of hospitalization for chronic complications and general medical conditions
for diabetic subjects were obtained from literature. Results were given for entire
population and per 10,000 inhabitants according to national census bureau.
RESULTS: According to self-reported data, a total of 896,727 hospitalizations were
estimated to be related to DM per year in SUS. This corresponds to 47 hospitaliza-
tions per 10,000 inhabitants annually in the whole population and can reach up to
318,2 per 10,000 when considering the group aged 75. Annual hospitalization
costs were estimated to be Brz$1,167,386,000 or Brz$61,197,90 per 10,000 inhabit-
ants (and Brz$398,058.61/10,000 for 75 population). When considering the expan-
sion of self-reported cases according to diagnosis rate, it was estimate 1,353,161
hospitalizations (70,8 per 10,000) and a total annual cost of Brz$1,778,992 (Brz$
93,140.65/10,000). CONCLUSIONS: DM and its complications are associated with a
relevant economic burden to SUS, especially when considering the elderly popu-
lation.
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OBJECTIVES: To assess the epidemiologic and economic burden of diabetes melli-
tus (DM) from a large population-based study. METHODS: Lombardy Region in-
cludes 9.9 million individuals. Its DM population was identified through a data
warehouse (DENALI), which matches with a probabilistic linkage demographic,
clinical and economic data of different Healthcare Administrative databases. All
individuals who during the year 2000 had an hospital discharge with a IDC-9 CM
code 250.XX, and/or two consecutive prescriptions of drugs for diabetes (ATC code
A10XXXX) within one year, and/or an exemption from co-payment health care
costs specific for DM, were selected and followed up to 9 years. We calculated
prevalence, mortality and health care costs (hospitalizations, drugs and outpatient
examinations/visits) from the National Health Service’s perspective. RESULTS: A
total of 312,223 eligible subjects were identified. The study population (51% male)
had a mean age of 66 (from 0.03 - 105.12) years at the index date. Prevalence was
0.4% among subjects aged 45 years, 3.0% (46-55 years), 7.2% (56-65 years), 11.1%
(66-75 years), 12.2% (76-85 years) and 10.1% (85 years). Overall 43.4 deaths/1,000
patients/year were estimated, significantly (p0.001) higher in men than women.
Overall, 3,315€/patient-year were spent on average: hospitalizations were the cost
driver (54.2% of total cost). Drugs contributed to 31.5%, outpatient claims repre-
sented 14.3% of total costs. As regards hospital costs, 35.6% was attributable to
admissions for cerebro/cardiovascular reasons, 4.3% to admission for DM reasons,
and 60.1% to any other reason. Class C drugs contributed to 33.5% of total drug
costs, 21.8%was attributable to class A (16.7% to class A10) and 4.3% to class B (2.4%
to class B01) drugs. CONCLUSIONS: . Merging different administrative databases
can providewithmany data from large populations observed for long time periods.
DENALI shows to be an efficient instrument to obtain accurate estimates of burden
of diseases such as diabetes mellitus.
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OBJECTIVES:Hospital readmissions are amajor concern for patients with diabetes
in terms of reduced quality of life and increased economic burden. The objective of
the studywas to identify predictors of readmissions among patients with diabetes.
METHODS: A retrospective analysis was conducted using the longitudinal data
from the Medical Expenditure Panel Survey (1999-2009), a set of nationally repre-
sentative surveys of individuals and their health-care providers across the United
States. Patients with a diabetes-related hospital admission during the survey pe-
riod were identified using the International Classification of Disease (ICD)-9 diag-
nosis code, ‘250’. These patients were followed for 12 months to determine if an-
other diabetes-related hospital admission occurred. A logistic regression to predict
readmission was developed and estimated. Covariates included age, gender, race,
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